Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Seraing – page 22

1 425 clinical trials in Seraing, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Seraing at a glance
1 425
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 425 trials in Seraing

Open in trial search

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AP31969 sulfate
  • Sponsor:Acesion Pharma ApS

Evaluating Hyperbaric Oxygen Treatment in Addition to Standard Care for Patients with Necrotizing Soft-Tissue Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Region Hovedstaden

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Seraing

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) optimization in patients with chronic usage patterns. The research evaluates various deprescribing strategies for individuals without clear long-term PPI indications.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Studies

This innovative trial compares on-demand medication use and alternative therapeutic approaches with traditional tapering methods, aiming to establish optimal deprescribing protocols in primary care settings.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.